01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
Immutep S.A. announced today the final results from its Phase I/II ...

---

10/2009 - New results confirm that ImmuFact IMP321 doubles clinical response rate
Immutep S.A. announced today interim results from the first three ...

---

09/2009 - Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells
Immutep S.A. announced today the publication of a clinical research ...

---

04/2009 - A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO)
Immutep S.A. announced today the first administration of IMP321 in ...

---

01/2009 - ImmuFact IMP321 associated with paclitaxel doubles clinical response rate
Immutep S.A. announced today interim results from its ongoing Phase ...